ELEKTA’S TECH PROWESS NEEDS THE BACKING OF A NEW CEO (BUY; 69% UPSIDE)
13/03/25 -" Since our March 2024 idea kicker for family-controlled Elekta (Buy; Sweden) entitled ELEKTA'S CINDERELLA STORY HAS A LONG WAY TO GO, the situation has deteriorated for this leading provider of ..."
Pages
60
Language
English
Published on
13/03/25
You may also be interested by these reports :
10/07/26
Following Thermo Fisher’s unsuccessful bid in 2020, Qiagen gradually restructured its business, focusing on non-COVID growth avenues. However, in ...
10/07/26
Non Pharma Health stocks have long been suffering. The sector has lost 39% ytd, not helped by EssilorLuxottica’s -35% correction. EL’s connected ...
23/06/26
There’s an interesting paradox at the heart of Sartorius Stedim Biotech’s (SSB; ADD; France) investment case. Since our last push in February 2025, ...
03/06/26
Despite a reduction in our target price, as discussed in the EPS section, our positive recommendation on Qiagen remains unchanged. This optimism is ...